Key Drivers
- Strong Liquidity
- No Revenue
- Cash Burn
AIAI Summary
ALLO is no longer a near-term financing story thanks to its cash runway and no debt, but the investment now hinges almost entirely on whether cema-cel/ALPHA3 and ALLO-316 can deliver durable clinical proof to justify the funding, since the chart and fundamentals still demand execution before a rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Cash Burn
ALLO has a very strong, debt-free balance sheet with abundant cash and liquidity, but zero revenue, persistent large losses, negative free cash flow, and a heavy accumulated deficit keep it fundamentally unprofitable.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Lower-High Pattern
- •Rebound Capped
Over the last month, ALLO remains in a short-term downtrend, but the bounce off $1.66-$1.75 shows support is holding while rallies still stall near $1.97-$2.00 and the prior $2.10-$2.15 ceiling.
Price fell from above $2.10 after
Sentiment & News
Key News Insights:
- •ALLO-316 efficacy
- •cema-cel momentum
- •Funding improvement
ALLO's July updates highlight meaningful pipeline progress, with strong ALLO-316 and cema-cel clinical data, new FDA designations, and a sturdier cash runway supporting the bull case.
These developments are likely positive for ALLO by strengthening regulatory visibility, de-risking the pipeline, and supporting investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings